Quantcast

Latest Endothelin Stories

Common Lung Blood Pressure Drug May Damage The Heart
2013-01-22 09:02:22

April Flowers for redOrbit.com - Your Universe Online A new study led by the Faculty of Medicine & Dentistry at the University of Alberta significantly improves understanding of how widely used drugs in pulmonary arterial hypertension (PAH) affect the heart health of patients who use them. The findings of this study, published in a recent issue of Circulation Research, a journal of the American Heart Association, reveal that the medications most often prescribed for PAH could block...

2011-07-25 12:30:19

Findings offer new hope for treatment of TBI in veterans wounded by explosions Bioengineers at Harvard have identified, for the very first time, the mechanism for diffuse axonal injury and explained why cerebral vasospasm is more common in blast-induced brain injuries than in brain injuries typically suffered by civilians. The research addresses two major aspects of traumatic brain injury (TBI), with significant implications for the medical treatment of soldiers wounded by explosions. Two...

2011-07-25 11:52:28

(Ivanhoe Newswire) "“ New findings offer new hope for the treatment of traumatic brain injury (TBI) in veterans wounded by explosions. Researchers have identified for the first time, the mechanism for diffuse axonal injury and explained why cerebral vasospasm is more common in blast-induced brain injuries than in brain injuries typically suffered by civilians. "These results have been a long time coming. So many young men and women are returning from military service with brain...

2011-05-04 10:00:00

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Aires Pharmaceuticals, Inc. today announced the hiring of Ed Parsley, D.O. as Chief Medical Officer. Dr. Parsley will fill a key role on Aires' leadership team and will be responsible for all clinical development activities for Aironite(TM), the company's lead product for treatment of pulmonary arterial hypertension (PAH). Dr. Parsley joins Aires from Pfizer where he was the Clinical Lead for ongoing clinical trials for Revatio (Sildenafil), Pfizer's...

2010-11-16 19:20:59

Scientists are learning more about how protein gets in the urine when the kidneys begin to fail and how a new drug blocks it. "We have known for a long time that renal failure comes with protein in your urine, especially in diabetes," said Dr. David Pollock, renal physiologist at the Medical College of Georgia Vascular Biology Center. It's also known that a new class of drugs called endothelin A receptor antagonists reduce protein in the urine. New research published in the journal...

2010-08-25 07:00:00

SOUTH SAN FRANCISCO, Calif., Aug. 25 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease....

2010-05-17 10:35:00

NEW ORLEANS, May 17 /PRNewswire-FirstCall/ -- Actelion Ltd (SIX: ATLN) announced today that findings from the REVEAL® (Registry to EValuate Early And Long-term PAH Disease Management) Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension (PAH) according to data presented at the American Thoracic Society's (ATS) Annual International Conference. The...

2010-04-22 05:00:00

SOUTH SAN FRANCISCO, Calif., April 22 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients. Simultaneously, the company has launched the PROSPECT registry, a multicenter,...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related